ArticleJournal of ophthalmic inflammation and infection2025
Long-term outcomes of intravitreal 0.19 mg fluocinolone acetonide implant in uveitic macular edema after prior local corticosteroid treatments.
Article in Journal of ophthalmic inflammation and infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study evaluates the long-term efficacy and safety of intravitreal 0.19 mg fluocinolone acetonide implant (FAi) in non-infectious UME, comparing it with prior sub-Tenon’s triamcinolone acetonide (STTA) and/or intravitreal dexamethasone implant (DEXAi).
methodsA retrospective review of patients with chronic non-infectious UME who received intravitreal FAi after STTA and/or DEXAi.
resultsThirteen eyes from 7 patients (69.2% female) were included, with a mean age of 65 ± 11 years. The median follow-up was 54 months before FAi (IQR: 43–65) and 47 months after FAi (IQR: 23–60). All eyes received at least one STTA, and 11 eyes received at least one DEXAi before FAi. The median number of injections before FAi was 4 (range: 2–8). A significant reduction in recurrences per year was observed after FAi (4.62 ± 1.9 before vs. 0.31 ± 0.5 after, Wilcoxon test, p = 0.001). Macular edema relapsed in 4 eyes (30.8%) between months 28 and 36. Central retinal thickness significantly decreased after FAi (474 ± 96 μm before vs. 305 ± 58 μm after, Wilcoxon test, p = 0.002). Ten eyes (76.9%) showed BCVA improvement (1–4 lines), and none lost visual acuity. All eyes were pseudophakic prior to FAi. At FAi, four of seven patients were on systemic anti-inflammatory therapy; 3 discontinued it, and none started new treatment after FAi. Five eyes were on topical IOP-lowering medication at the time of FAi; 2 required and increase in treatment, and 2 later underwent trabeculectomy. After FAi, only two eyes started IOP-lowering medication.
conclusionsIn this case series with long-term follow-up, FAi for non-infectious UME was effective, safe, and reduced recurrences compared to other local corticosteroids.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.